At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Gareth Morgan (University of Arkansas for Medical Sciences, Little Rock, AR; The Institute of Cancer Research, London, UK) discusses high-throughput genetic profiling with an all-molecular diagnostic test for recurrent structural aberrations in multiple myeloma. It is hoped this approach will enable molecular risk-stratified clinical trial design and risk-adapted precision medicine for high-risk patients.